Pharma Focus Asia

Bristol Myers Squibb Introduced Breakthrough Breyanzi ® CAR T Cell Therapy

Bristol Myers Squibb has introduced Breyanzi® as the first CAR T cell therapy designed specifically for adults facing relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

Breyanzi® is characterized by its CD19-directed CAR T cell therapy, featuring a 4-1BB costimulatory domain. This specific targeting enhances the expansion and persistence of the CAR T cells in the patient's body.

Breyanzi® is made from the patient's own T cells, which are collected and genetically reengineered to become CAR T cells. This personalised approach offers a tailored treatment option for each patient.

Breyanzi® is delivered via infusion as a one-time treatment. This contrasts with conventional therapies, which often require ongoing treatment regimens.

Clinical trials have demonstrated that Breyanzi® provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, including specific inhibitors.

The introduction of Breyanzi® expands access to CAR T cell therapy across a broad array of B-cell malignancies. This addresses the critical unmet need for effective treatment options in these conditions.

Breyanzi® represents a shift in the treatment paradigm for CLL and SLL. Instead of continuous therapy with sequential regimens to overcome drug resistance, Breyanzi® offers a one-time personalised T-cell based approach that has the potential to provide complete and lasting remission.
 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024